SurgiPals

SurgiPals appears to be an early-stage pediatric medtech/digital health venture rather than a traditional biotech or pharma company. Publicly available evidence is limited, but the company was identified in 2020 as a finalist in a pediatric medical device competition organized by Children’s National and NCC-PDI, where its product was described as a digital assistant and urine biochemical sensor for outpatient care of children with COVID-19. Based on the available information, SurgiPals seems focused on remote pediatric monitoring and decision support rather than drug development. No evidence was found of clinical-stage therapeutics, a broader drug pipeline, public-market listing, or a completed acquisition. The company’s public footprint is sparse, so many corporate and financial details cannot be verified from accessible sources.